by: laura tennant
more effective treatments for an aggressive treatment-resistant form of breast cancer known as her2+ breast cancer may be on the horizon, according to new research from the université de montréal.
the
study
, which was published in pnas, found a promising potential target for treating her2+ breast cancer. the team was led by professor jean-françois côté and his doctoral student marie-anne goyette at the cytoskeleton organization and cell-migration research unit of the udem-affiliated montreal clinical research institute.
“our study provides new evidence [for] a therapeutic target in her2+ breast cancer metastasis,” côté said.
her2 stands for human epithelial growth factor 2. her2+ breast cancer is an aggressive form of the disease associated with treatment resistance and a poor prognosis. approximately 20 per cent of breast cancer is her2+, according to the
canadian breast cancer network
.
human epithelial growth factor 2 is a protein on the cell surface that promotes growth. when breast cancer cells are positive for her2, the cancer cells
overexpress
the her2 gene, leading to faster growth and a higher chance of metastasis.
cancer can become life-threatening when it metastasizes, spreading to other organs and systems in the body. if the cancer is able to invade these other systems, it can then begin to shut down essential bodily functions.